# 510(k) Summary

# Contact Person

Submitter's Name/Address   
Abbott Laboratories   
1921 Hurd Drive   
Irving, TX 75038   
Linda Morris   
Senior Regulatory Specialist, MS 2- 1 1   
Regulatory Affairs   
(972) 518-6711   
Fax (972) 518-7479

April 26, 2006

Creatinine

Date of Preparation of this Summary:   
Device Trade or Proprietary Name:   
Device Common/Usual Name or   
Classification Name:   
Classification Number/Class:   
Product Code:

Creatinine

Class II 862.1125

CGX

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: k 0 6 1193

# Test Description:

Creatinine is an in vitro diagnostic assay for the quantitative analysis of creatinine in human serum, plasma, or urine. At an alkaline $\mathsf { p H } ,$ creatinine in the sample reacts with picrate to form a creatinine-picrate complex. The rate of increase in absorbance at ${ 5 0 0 } \mathrm { n m }$ due to the formation of this complex is directly proportional to the concentration of creatinine in the sample.

# Substantial Equivalence:

The Creatinine assay is substantially equivalent to the Roche Creatinine assay (K941837) on the Hitachi 917 Analyzer. Both assays yield similar Performance Characteristics.

# Similarities:

Both assays can be used for the quantitation of creatinine.   
Both assays yield similar results.   
Both assays are based on the modified Jfe (creatinine alkaline picrate methodology. Both assays use serum, plasma, and urine

# Differences:

# None

# Intended Use:

The Cret   e  i rp urine.

# Performance Characteristics:

Comparative performance studies were conducted using the AEROSET System.

The Creatinine assay method comparison yielded acceptable correlation with the Creatinine assay on the Hitachi 917 Analyzer. The AEROSET System showed a correlation coefficient of 0.9996, slope of 0.98, and Y-intercept of - 0.19 mg/dL for the serum application and a correlation coefficient of 0.9992, slope of 0.94, and Y-intercept of  3.66 mg/dL for the urine application when compared to the Hitachi 917 Analyzer. The ARCHITECT c8000 System showed a correlation coefficient of 0.9993, slope of 0.96, and Y-intercept of  0.24 mg/dL for the serum application and a correlation coefficient of 0.9990, slope of 0.93, and Y-intercept of  4.16 mg/ for the urie application when compared to the Hitaci 917 Analyzer. The ARCHITECT c8000 System showed a correlation coefficient of 0.9996, slope of 0.98, and Y-intercept of  0.06 mg/dL for the serum application and a correlation coefficient of 0.9997, slope of 0.99, and Y-intercept of - 0.51 mg/dL for the urine application when compared to the AEROSET System. The Creatinine assay method comparison yielded acceptable correlation between the AEROSET System and the ARCHITECT c8000 System.

Precision studies were conducted using the Creatinine assay. On the AEROSET System, the total $\% \mathbf { C V }$ for Level 1 is $4 . 9 5 \% .$ and Level 2 is $3 . 1 8 \%$ for the serum application and the total $\% \times \mathrm { v }$ for Level 1 is $2 . 4 1 \%$ , and Level 2 is $2 . 4 1 \%$ for the urine application. On the ARCHITECT $\pmb { c 8 0 0 0 }$ System, the total $\% \times \mathrm { c v }$ for Level 1 is $3 . 1 0 \% ,$ and Level 2 is $1 . 5 4 \%$ for the serum application and the total $\% C V$ for Level 1 is $0 . 9 4 \%$ and Level 2 is $0 . 9 9 \%$ for the urine application.

The Creatinie assayis inear from0.20 to $3 7 . 0 0 \mathrm { m g / d L }$ for the serum application.

The Creatinine assay is inear from 5.0 to $7 4 0 . 0 \mathrm { m g / d L }$ for the urine application. The limit of qantitation (sensitivity) of the Creatinie assay is 0.10 mg/L for the serum application, and ${ 2 . 0 \ m g / \mathrm { d L } }$ for the urine application.

The dat demonstrate that the perormancef the Creatinie assay is substantially equivalent to the performance of the Creatinine assay on the Hitachi 917 Analyzer.

# Conclusion:

The Creatinine assay on the AEROSET and the ARCHITECT c8000 Systems is substantially euivalent theRocheCreatinassay  the Hitachi91Analyzer demostrae by results obtained in the studies.

Ms. Linda Morris Sr. Regulatory Specialist ADD Regulatory Affairs Abbott Laboratories Inc. 1921 Hurd Drive Irving, TX 75038

# JUN 2 3 2006

Re: k061193 Trade/Device Name: Abbott Clinical Chemistry Creatinine Regulation Number: 21 CFRÂ§862.1225 Regulation Name: Creatine test system Regulatory Class: Class II Product Code: CGX Dated: April 26, 2006 Received: April 28, 2006

Dear Ms. Morris:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28. 1976. the enactment date of the Medical Device Amendments. or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PM.A). You may. therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA). it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21. Code of Federal Regulations (CFR), Parts 800 to 895. In addition. FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the . Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including. but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809): and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) al quvavi marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/7447271691b31123aca484e91eb0fddf4b3876d4edf0612be7b53222c5d4279c.jpg)

Alberto Gutierrez, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): K 06 1193

Device Name: Abbott Clinical Chemistry Creatinine

Indications For Use:

A creatinine test system is a device intended to measure creatinine levels in serum, plasma, and urine. Creatinine measurements are used in the diagnosis and treatment of renal diseases, in monitoring renal dialysis, and as a calculation basis for measuring other urine analytes.

Concurrence of CDRH. Office of In Vitro Diagnostic Devices (OIVD)

![](images/b70acb4945c6a6a91838282ce33471ee6836c0b7c654a7806bbaefb7e339a704.jpg)

Page 1 of